CA2185457A1 - Use of nitric oxide-releasing polymers to treat restenosis and related disorders - Google Patents

Use of nitric oxide-releasing polymers to treat restenosis and related disorders

Info

Publication number
CA2185457A1
CA2185457A1 CA002185457A CA2185457A CA2185457A1 CA 2185457 A1 CA2185457 A1 CA 2185457A1 CA 002185457 A CA002185457 A CA 002185457A CA 2185457 A CA2185457 A CA 2185457A CA 2185457 A1 CA2185457 A1 CA 2185457A1
Authority
CA
Canada
Prior art keywords
nitric oxide
releasing
related disorders
delivery means
restenosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002185457A
Other languages
French (fr)
Other versions
CA2185457C (en
Inventor
Larry K. Keefer
Thomas C. Hutsell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Comedicus Inc
Original Assignee
Larry K. Keefer
Thomas C. Hutsell
Comedicus, Inc.
The United States Of America, Represented By The Secretary, Department O F Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Larry K. Keefer, Thomas C. Hutsell, Comedicus, Inc., The United States Of America, Represented By The Secretary, Department O F Health And Human Services filed Critical Larry K. Keefer
Publication of CA2185457A1 publication Critical patent/CA2185457A1/en
Application granted granted Critical
Publication of CA2185457C publication Critical patent/CA2185457C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
    • C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines

Abstract

Methods of amelioration, treatment and prevention for restenosis and related disorders are provided. Methods involve the administration of nitric oxide by a nitric oxide delivery means comprising a restenosis-ameliorating or therapeutically/prophylactically effective amount of a polymer to which is bound a nitric oxide-releasing N2O2- functional group or a compound comprising a nitric oxide-releasing N2O2- functional group. Also provided are nitric oxide delivery means comprising such nitric oxide-releasing polymers or compounds for use in such methods. Preferably, the delivery means is coated with a nitric oxide-releasing polymer, which may be biodegradable, and enables the controllable and predictable release of NO to a given site in such a manner that effective ameliorating, prophylactic or therapeutic dosing is realized.
CA002185457A 1994-03-17 1995-03-09 Use of nitric oxide-releasing polymers to treat restenosis and related disorders Expired - Fee Related CA2185457C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US214,372 1994-03-17
US08/214,372 US5650447A (en) 1992-08-24 1994-03-17 Nitric oxide-releasing polymers to treat restenosis and related disorders
PCT/US1995/003040 WO1995024908A1 (en) 1994-03-17 1995-03-09 Use of nitric oxide-releasing polymers to treat restenosis and related disorders

Publications (2)

Publication Number Publication Date
CA2185457A1 true CA2185457A1 (en) 1995-09-21
CA2185457C CA2185457C (en) 2004-05-25

Family

ID=22798839

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002185457A Expired - Fee Related CA2185457C (en) 1994-03-17 1995-03-09 Use of nitric oxide-releasing polymers to treat restenosis and related disorders

Country Status (11)

Country Link
US (1) US5650447A (en)
EP (1) EP0752866B1 (en)
JP (1) JPH10502905A (en)
AT (1) ATE218352T1 (en)
AU (1) AU698525B2 (en)
CA (1) CA2185457C (en)
DE (1) DE69526934T2 (en)
DK (1) DK0752866T3 (en)
ES (1) ES2177637T3 (en)
PT (1) PT752866E (en)
WO (1) WO1995024908A1 (en)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5632981A (en) * 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US6255277B1 (en) 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
CA2206119C (en) * 1994-12-12 2008-05-13 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US20050152950A1 (en) * 1995-11-13 2005-07-14 Saffran Bruce N. Method and apparatus for macromolecular delivery using a coated membrane
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
AU3986097A (en) * 1996-08-27 1998-03-19 University Of Akron, The Lipophilic polyamine esters for the site specific delivery of nitric oxide in pharmaceutical use
US6372796B1 (en) * 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
US5994444A (en) * 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US5962520A (en) * 1998-04-02 1999-10-05 The University Of Akron Hydrolytically unstable, biocompatible polymer
US6207855B1 (en) * 1998-06-23 2001-03-27 Duke University Medical Center Stable no-delivering compounds
US20040043068A1 (en) * 1998-09-29 2004-03-04 Eugene Tedeschi Uses for medical devices having a lubricious, nitric oxide-releasing coating
US7018365B2 (en) 1999-05-21 2006-03-28 Micro Therapeutics, Inc. Threaded syringe with quick stop
US6645167B1 (en) * 1999-05-21 2003-11-11 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an embolizing composition
JP2003500106A (en) * 1999-05-21 2003-01-07 マイクロ・セラピューティクス・インコーポレーテッド Method for delivering uniformly dispersed high viscosity embolic compositions in vivo
EP1207811A4 (en) * 1999-08-04 2007-03-07 Bard Inc C R Nitric oxide releasing medical devices
US7597698B2 (en) * 1999-08-10 2009-10-06 Maquet Cardiovascular Llc Apparatus and method for endoscopic encirclement of pulmonary veins for epicardial ablation
US7288096B2 (en) 2003-01-17 2007-10-30 Origin Medsystems, Inc. Apparatus for placement of cardiac defibrillator and pacer
US20030187461A1 (en) * 1999-08-10 2003-10-02 Chin Albert K. Releasable guide and method for endoscopic cardiac lead placement
US20040102804A1 (en) * 1999-08-10 2004-05-27 Chin Albert K. Apparatus and methods for endoscopic surgical procedures
US7398781B1 (en) * 1999-08-10 2008-07-15 Maquet Cardiovascular, Llc Method for subxiphoid endoscopic access
US7526342B2 (en) * 1999-08-10 2009-04-28 Maquet Cardiovascular Llc Apparatus for endoscopic cardiac mapping and lead placement
US6569082B1 (en) 1999-08-10 2003-05-27 Origin Medsystems, Inc. Apparatus and methods for cardiac restraint
US20060287574A1 (en) * 1999-08-25 2006-12-21 Chin Albert K Longitudinal dilator
US6660260B1 (en) 1999-09-21 2003-12-09 Mayo Foundation For Medical Education And Research Bioprosthetic heart valves
JP2003520830A (en) 2000-01-25 2003-07-08 エドワーズ ライフサイエンシーズ コーポレイション Delivery system for treatment of restenosis and anastomotic intimal hyperplasia
US6270779B1 (en) * 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
EA005649B1 (en) 2000-08-11 2005-04-28 Дэвид Р. Уитлок Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
US20050043506A1 (en) * 2000-09-27 2005-02-24 Michigan Biotechnology Institute Polyamide materials based on unsaturated carboxylic acids and amines
US6797743B2 (en) * 2000-09-27 2004-09-28 Michigan Biotechnology Institute Antimicrobial polymer
CA2409104A1 (en) 2000-10-11 2002-04-18 Micro Therapeutics, Inc. Methods for treating aneurysms
AU9463401A (en) 2000-10-16 2002-04-29 Conor Medsystems Inc Expandable medical device for delivery of beneficial agent
US7049308B2 (en) * 2000-10-26 2006-05-23 Duke University C-nitroso compounds and use thereof
US6565601B2 (en) * 2000-11-15 2003-05-20 Micro Therapeutics, Inc. Methods for vascular reconstruction of diseased arteries
WO2002051383A2 (en) * 2000-12-27 2002-07-04 Genzyme Corporation Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
DE60233140D1 (en) 2001-05-02 2009-09-10 Nitromed Inc NITROSED AND NITROSYLATED NEBIVOLOL AND ITS METABOLITES, COMPOSITIONS AND METHOD OF USE
AU2002336761A1 (en) * 2001-09-26 2003-04-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Nitric oxide-releasing coated medical devices and method of preparing same
US6703046B2 (en) * 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
CA2473097A1 (en) * 2002-01-11 2003-07-17 David R. Whitlock Compositions including ammonia oxidizing bacteria and methods of using same
US6939554B2 (en) * 2002-02-05 2005-09-06 Michigan Biotechnology Institute Antimicrobial polymer
WO2003080730A1 (en) 2002-03-20 2003-10-02 Michigan Biotechnology Institute Conductive polymer-based material
WO2003080039A1 (en) * 2002-03-21 2003-10-02 The University Of Utah Research Foundation In vivo use of glutathionone s-transferase activated nitric oxide donors
AU2003234510A1 (en) * 2002-05-07 2003-11-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
WO2003095623A2 (en) * 2002-05-10 2003-11-20 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
JP2005534485A (en) 2002-08-02 2005-11-17 アメリカ合衆国 Cross-linked nitric oxide-releasing polyamine-coated substrate, composition containing it and method for its production
US6951902B2 (en) * 2002-08-16 2005-10-04 Michigan Biotechnology Institute Two dimensional polymer that generates nitric oxide
AU2004226327A1 (en) 2003-03-28 2004-10-14 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
AU2004233347A1 (en) * 2003-04-23 2004-11-04 Darrell H. Reneker Sequestered reactive materials
BRPI0412273B1 (en) * 2003-07-03 2019-09-24 The University Court Of The University Of St. Andrews PHARMACEUTICAL PREPARATION, USE OF A ZEOLITE MATERIAL, MEDICAL ARTICLE, COSMETIC PRODUCT AND / OR PERSONAL HYGIENE, AND NITRIC OXIDE RELEASE METHOD
AU2004266705A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005023183A2 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
WO2005067815A1 (en) * 2004-01-05 2005-07-28 Zygo Corporation Stage alignment in lithography tools
US20090131342A1 (en) * 2004-01-22 2009-05-21 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
JP2007526911A (en) * 2004-01-22 2007-09-20 ザ ユニバーシティ オブ アクロン Polymer NO Donor Predrug Nanofiber Coating for Medical Devices and Therapy
US20050165452A1 (en) * 2004-01-28 2005-07-28 Medtronic, Inc. Antithrombogenic medical device
CA2555591C (en) * 2004-02-09 2011-01-04 Amulet Pharmaceuticals, Inc. Nitric oxide-releasing polymers
US20070191377A1 (en) * 2004-03-31 2007-08-16 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
US20060039950A1 (en) * 2004-08-23 2006-02-23 Zhengrong Zhou Multi-functional biocompatible coatings for intravascular devices
WO2006037105A2 (en) 2004-09-27 2006-04-06 Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
AU2005304770A1 (en) * 2004-11-08 2006-05-18 Nicox S.A. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
WO2006084914A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Device for gastric treatment and manufacturing process for the same
MX2007009690A (en) * 2005-02-11 2007-10-15 Nolabs Ab Device method, and use for treatment of neuropathy involving nitric oxide.
EP1690532A1 (en) * 2005-02-11 2006-08-16 NOLabs AB Device for gastric treatment and manufacturing process for the same
JP2008531697A (en) * 2005-02-28 2008-08-14 ニトロメッド インコーポレーティッド Cardiovascular compounds containing nitric oxide enhancing groups, compositions and methods of use
WO2006099058A2 (en) * 2005-03-09 2006-09-21 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
US20090075956A1 (en) * 2005-04-07 2009-03-19 Nitromed, Inc. Genetic Risk Assessment in Heart Failure: Impact of the Genetic Variation of NOS3
US20090048219A1 (en) * 2005-05-23 2009-02-19 Nitromed Inc. Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
JP5274248B2 (en) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Nitric oxide releasing particles for nitric oxide therapy and biomedical applications
ATE513568T1 (en) * 2005-06-30 2011-07-15 Accord Biomaterials Inc NITROGEN OXIDE COATINGS FOR MEDICAL DEVICES
US20080241208A1 (en) * 2005-06-30 2008-10-02 Charles Shanley Methods, Compositions and Devices For Promoting Anglogenesis
US20080262330A1 (en) * 2005-06-30 2008-10-23 Reynolds Melissa M Analyte Sensors and Compositions for Use Therein
EP1915157A4 (en) 2005-08-02 2010-09-01 Nicox Sa Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
JP2009505727A (en) * 2005-08-25 2009-02-12 メドトロニック ヴァスキュラー インコーポレイテッド Nitric oxide releasing biodegradable polymers useful as medical devices and their coatings
US20070053952A1 (en) * 2005-09-07 2007-03-08 Medtronic Vascular, Inc. Nitric oxide-releasing polymers derived from modified polymers
US20090192128A1 (en) * 2005-10-04 2009-07-30 Nitromed Inc. Genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism
CA2628055C (en) * 2005-10-31 2013-10-01 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
US7838023B2 (en) * 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
CA2632224A1 (en) * 2005-12-02 2007-06-07 The Regents Of The University Of Michigan Polymer compositions, coatings and devices, and methods of making and using the same
JP2009518516A (en) * 2005-12-06 2009-05-07 アミュレット ファーマシューティカルズ インコーポレイティッド Nitric oxide releasing polymer
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
US8067414B2 (en) 2006-03-29 2011-11-29 Nicox S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8241619B2 (en) * 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
WO2009064861A2 (en) * 2007-11-13 2009-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitric oxide-releasing diazeniumdiolated polymers, compositions, medical devices, and uses thereof
US20090170933A1 (en) * 2007-12-26 2009-07-02 Cook Incorporated Method for removing a medical device from a spasmodic constriction in a bodily passageway
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
CN102014870A (en) * 2008-03-07 2011-04-13 犹他州大学研究基金会 Activated nitric oxide donors and methods of making and using thereof
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
WO2009123713A1 (en) 2008-04-01 2009-10-08 Cornell University Organo-soluble chitosan salts and chitosan-derived biomaterials prepared thereof
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
EP2432425B1 (en) 2009-05-20 2018-08-08 480 Biomedical, Inc. Medical implant
US20110319987A1 (en) 2009-05-20 2011-12-29 Arsenal Medical Medical implant
RS56496B1 (en) 2009-06-09 2018-01-31 Prolong Pharmaceuticals Llc Hemoglobin compositions
CN102695528B (en) 2009-08-21 2016-07-13 诺万公司 Wound dressing, its using method and forming method thereof
CA3062005C (en) 2009-08-21 2022-02-15 Novan, Inc. Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
US8372133B2 (en) * 2009-10-05 2013-02-12 480 Biomedical, Inc. Polymeric implant delivery system
US20110301299A1 (en) 2010-06-08 2011-12-08 Medtronic Vascular, Inc. Medical Devices and Polymers Therefor Having PTFE Surfaces Modified With Nitric Oxide-Releasing Polymers
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (en) 2011-02-28 2019-01-02 Novan Inc Silica particles modified with S-nitrosothiol that release nitric oxide and methods of manufacturing them
WO2012153331A2 (en) 2011-05-09 2012-11-15 Topical Therapeutic Agent (Tta) Ltd. Nitric oxide-sequestering topical formulations
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
WO2015160911A2 (en) 2014-04-15 2015-10-22 Aobiome Llc Ammonia-oxidizing nitrosomonas eutropha strain d23
EP3180366B1 (en) * 2014-08-14 2018-09-26 Rohm and Haas Company Polymer with releasable gas
CA2975573C (en) 2015-02-03 2023-08-01 University Court Of The University Of St Andrews No containing compositions
US11186681B2 (en) 2016-10-07 2021-11-30 The University Of North Carolina At Chapel Hill S-Nitrosothiol-mediated hyperbranched polyesters
CA3048785A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
CA3055474A1 (en) 2017-03-28 2018-10-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
AU2019231712A1 (en) 2018-03-06 2020-10-15 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
US11421044B2 (en) 2018-12-28 2022-08-23 The University Of North Carolina At Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto
WO2023081681A1 (en) * 2021-11-03 2023-05-11 Baxter International Inc. Nitric oxide donors for use in surgical recovery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA998495A (en) * 1971-04-15 1976-10-12 Snamprogetti S.P.A. Modified polyisoprene and process for the preparation thereof
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US5208233A (en) * 1989-09-15 1993-05-04 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
US5185376A (en) * 1991-09-24 1993-02-09 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic inhibition of platelet aggregation by nucleophile-nitric oxide complexes and derivatives thereof
US5219710A (en) * 1991-11-25 1993-06-15 Allied-Signal Inc. Polymeric nitrones having a styrene-derived backbone chain

Also Published As

Publication number Publication date
DK0752866T3 (en) 2002-09-16
ES2177637T3 (en) 2002-12-16
DE69526934D1 (en) 2002-07-11
CA2185457C (en) 2004-05-25
EP0752866A1 (en) 1997-01-15
JPH10502905A (en) 1998-03-17
US5650447A (en) 1997-07-22
AU1988995A (en) 1995-10-03
ATE218352T1 (en) 2002-06-15
DE69526934T2 (en) 2003-01-02
WO1995024908A1 (en) 1995-09-21
AU698525B2 (en) 1998-10-29
EP0752866B1 (en) 2002-06-05
PT752866E (en) 2002-11-29

Similar Documents

Publication Publication Date Title
CA2185457A1 (en) Use of nitric oxide-releasing polymers to treat restenosis and related disorders
WO2002069963A3 (en) Compositions comprising ferulic acid, caffeic acid, tannic acid or ellagic acid and their use for the preparation of a medicament for the treatment of dermatological disorders
CA2296336A1 (en) Analgesic compositions comprising anti-epileptic compounds and methods of using same
WO1999025395A3 (en) Improved wound dressing device
CA2111836A1 (en) Spin-trapping pharmaceutical compositions and methods for use thereof
CA2214097A1 (en) Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
CA2130805A1 (en) Use of mannose phosphates for the treatment of fibrotic disorders
EP1688143A3 (en) Niacin-containing substained-release tablets and kits
CA2274074A1 (en) Novel compounds with analgesic effect
AU2002236470A1 (en) Uses for medical devices having a lubricious, nitric oxide-releasing coating for the therapy of vascular disorders
IL126589A (en) 2,3-disubstituted-4-(3h)-quinazolinones, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating or preventing cerebral deficits
CA2337750A1 (en) Therapeutic or cosmetic compositions containing dimeric or polymeric forms of hydroxyacids, and their therapeutic use
IL133434A (en) Use of polyamine polymers in the preparation of medicaments for removing bile salts and for treating hypercholesterolemia
EP0244080A3 (en) Medicament for the treatment of obesity
CA2189916A1 (en) A new regime for paclitaxel in kaposi&#39;s sarcoma patients
CA2143413A1 (en) Local Drug Delivery Film, for Periodontal Treatment
CA2154103A1 (en) Treatment of Mucous Membrane Disease, Trauma or Condition and for the Relief of Pain
CA2139385A1 (en) Products containing g-csf and tnf binding protein
CA2108963A1 (en) Compositions and Methods for Therapy and Prevention of Cancer, Aids and Anemia
WO2000069255A8 (en) Anti-inflammatory therapy for inflammatory mediated infection
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
CA2131991A1 (en) Treatment of Migraine
AU1546101A (en) Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
EP1806144A3 (en) Use of SARP-1 for the treatment and/or prevention of scleroderma

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed